TimesSquare Capital Management LLC Reduces Holdings in DexCom, Inc. (NASDAQ:DXCM)

TimesSquare Capital Management LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 697,265 shares of the medical device company's stock after selling 7,215 shares during the period. TimesSquare Capital Management LLC owned 0.18% of DexCom worth $46,745,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom during the 2nd quarter worth about $25,000. Sachetta LLC increased its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after acquiring an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom during the first quarter valued at about $29,000. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC increased its position in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after buying an additional 315 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Activity

In other news, EVP Sadie Stern sold 426 shares of the company's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company's stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company's stock.

DexCom Trading Up 1.5 %

Shares of NASDAQ DXCM traded up $1.05 during midday trading on Friday, reaching $69.96. 3,153,680 shares of the stock were exchanged, compared to its average volume of 4,825,686. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market capitalization of $27.33 billion, a P/E ratio of 41.89, a PEG ratio of 2.10 and a beta of 1.17. The company has a 50 day simple moving average of $69.66 and a 200 day simple moving average of $93.42. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Leerink Partners decreased their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday, October 25th. Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group restated a "buy" rating and set a $145.00 price target on shares of DexCom in a research report on Tuesday, July 23rd. BTIG Research decreased their price objective on shares of DexCom from $156.00 to $120.00 and set a "buy" rating for the company in a research report on Friday, July 26th. Finally, Barclays reduced their price target on DexCom from $138.00 to $113.00 and set an "equal weight" rating for the company in a report on Monday, July 29th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.